Mega Millions For Intercept Pharmaceuticals Shareholders. What's Next?

Jan 11 2014, 11:31am CST | by

When thinking of mega millions winners, we usually think of people who purchased lucky lottery tickets. This week, we should count as mega millions winners another category: investors who purchased shares in a small biotechnology company, Intercept Pharmaceuticals, Inc., before the closing of Wall Street on Wednesday — at around $72 or better at the 52wk low of $30.38.

The stock climbed to $275.87 on Thursday, and to $497 during the trading time on Friday, valuing the company close to $9 billion.

Now, think of the company insiders who held roughly 43 percent of the 13.4m of outstanding shares; the institutions, who held another 26 percent; and the individuals who held a few thousand before Thursday.

You can do the math.

The catalyst for these astronomical gains? The company’s liver-disease drug, which performed unexpectedly well in a clinical trial.

“The drug, called obeticholic acid, or OCA, mimics a naturally occurring human bile acid that Intercept believes has liver-protective properties,” writes Peter Loftus of Wall Street Journal.

But does the potential market for the drug justify the company’s current valuation?

ICPT key statistics

Market cap (intraday) 8.73B
Shares Outstanding 19.34M
%Held by insiders 42.7%
%Held by institutions 26.10%
Revenue 1.62M
Operating Cash Flow -21.87M

Source:Yahoo.Finance.com1/10/14

Obviously, investors buying shares on Friday believe so. I would be skeptical, however, for a number of reasons:

First, we are talking about a drug that performed well in a statistical trial, not a drug that has already received FDA approval. “Many experimental drugs fail to make it to the market, so Intercept’s OCA could stumble,” continues Peter Loftus. “But the clinical trial outcome raised investors’ expectations that the company could have a big-selling product on hands.”

Second, even if OCA receives an expedient FDA approval, marketing success is no guarantee. Investors have to look no further than the fate of Dendreon’s drug PROVENGE that received FDA approval a few years ago.

Third, even if OCA passes both the FDA and the market test, at the current market valuation, the company is valued at 10 percent of the value of Amgen Inc., which has been around for more than three decades and has several blockbuster stocks in the market.

Investors who have been around Wall Street long enough remember EntreMed Inc, another biotechnology company that displayed a similar performance in a short period. We all know what happened in that case.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

3 Steps To Landing A Web Designer Internship
As a web designer myself, I can relate to young web designers who are just starting out and looking for a way to get their foot in the door. It’s very hard to start because many companies are looking for experienced...
 
 
4 Dow Stocks Under Accumulation
The choppy nature of the 1st quarter is not surprising after the action in 2013. The sharp declines in the Nasdaq 100 and biotechnology stocks have caused some technical damage that would normally take time to repair....
 
 
Bank Deposits, Structuring, and Asset Forfeitures
This is a version of an article originally published in the Winter 2014 issue of the White Collar Crime Committee Newsletter, Criminal Justice Section, American Bar Association.  For the original article, including full...
 
 
Is Big Data A Potential Distraction?
Over recent months, I’ve read numerous articles that have reported that many executives are struggling with ‘Big Data’. In fact, many studies report that upwards of 50-60% of executives say that their firms are weak or...
 
 
 

Latest from the Network

VW banks on China to reach part of its 2018 goal this year - CEO
Strong sales growth in China will help Germany’s Volkswagen AG clinch its sales target of 10 million vehicles annually well ahead of 2018, the current objective, VW Chief Executive Martin Winterkorn said at the start of...
Read more on Auto Balla
 
3 Steps To Landing A Web Designer Internship
As a web designer myself, I can relate to young web designers who are just starting out and looking for a way to get their foot in the door. It’s very hard to start because many companies are looking for experienced...
Read more on Business Balla
 
4 Dow Stocks Under Accumulation
The choppy nature of the 1st quarter is not surprising after the action in 2013. The sharp declines in the Nasdaq 100 and biotechnology stocks have caused some technical damage that would normally take time to repair....
Read more on Business Balla
 
Bank Deposits, Structuring, and Asset Forfeitures
This is a version of an article originally published in the Winter 2014 issue of the White Collar Crime Committee Newsletter, Criminal Justice Section, American Bar Association.  For the original article, including full...
Read more on Business Balla
 
Is Big Data A Potential Distraction?
Over recent months, I’ve read numerous articles that have reported that many executives are struggling with ‘Big Data’. In fact, many studies report that upwards of 50-60% of executives say that their firms are weak or...
Read more on Business Balla
 
Does Doing Good In Business Imply Doing Less Well?
Many entrepreneurs still don’t understand that building a business culture today of doing good, like helping people (society) and planet (sustainability), is also a key to maximizing profit. Employees and customers...
Read more on Business Balla
 
Melissa Joan Hart: Celebrity pressure is gym motivation
Melissa Joan Hart admits the pressure of being a celebrity encourages her to go to the gym. The 38-year-old actress - who gained 60lbs while pregnant with her third child in 2012 - recently lost a dramatic 40lbs and...
Read more on Celebrity Balla
 
iPad Sales Predicted to Decrease in Q2 2014
The iPad might be unable to generate a blockbuster sale in the second quarter of 2014, as a new report claims that the device might experience a declined sale in the specific period.The report has been published by...
Read more on Apple Balla
 
New Photos Reveal the iPad Air 2 with Integrated Front Panel and Display
The next model of iPad Air might get a thinner shape, as a number of photos reveal that the device will include its front panel integrated with the display, rather than being separated.The photos have been unveiled by...
Read more on Apple Balla
 
Pebble Is Winning The Wearables War and What That Means For The iWatch
Some suggestive data indicates that the Pebble smartwatch, which sold 400,000 units in 2013, has the most staying power of the first batch of consumer wearables. null Want a clear indication that what these numbers show...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla